Goldman Sachs Upgrades Thermo Fisher on Life Tech Buy, Improving End Markets | GenomeWeb

NEW YORK (GenomeWeb News) – Goldman Sachs today upgraded Thermo Fisher Scientific' stock, noting the firm's increased scale as a result of its purchase of Life Technologies, as well as improving end markets.

The investment bank lifted Thermo Fisher's shares to a Buy rating from a previous Neutral rating and increased the 12-month price target on its stock to $153 from $114.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

An opinion piece in the New York Times urges lawmakers to keep genetic protections in place.

Research funding in Canada is to remain mostly the same, ScienceInsider reports.

In Science this week: random DNA replication errors play role in cancer, and more.

The Bill and Melinda Gates Foundation embarks on an open-access publishing path.